12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ABT-450 plus ritonavir/ABT-267/ABT-333: Phase III data

The double-blind, placebo-controlled, international Phase III SAPPHIRE-II (Study M13-098) trial in 394 patients with chronic HCV genotype 1 infection and no evidence of liver cirrhosis who previously failed peginterferon and ribavirin showed that AbbVie's all-oral 3D regimen - comprising co-administration with once-daily 150 mg ABT-450 plus 100 mg ritonavir, once-daily 25 mg ABT-267 and twice-daily 250 mg ABT-333 - with ribavirin for 12 weeks led to an SVR 12 weeks after the end of treatment in 96% of patients in the active treatment arm (n=297). SVR12 rates were 96% in patients with HCV genotype 1a infection (n=173) and 97% in patients with HCV genotype 1b infection (n=123)....

Read the full 514 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >